USA Alpha- Antitrypsin Deficiency Treatment Market Report 2019

Table of Contents

1 Report Overview

• 1.1 Definition and Specification
• 1.2 Report Overview
  • 1.2.1 Manufacturers Overview
  • 1.2.2 Regions Overview
  • 1.2.3 Type Overview
  • 1.2.4 Application Overview
• 1.3 Industrial Chain
  • 1.3.1 Alpha- Antitrypsin Deficiency Treatment Overall Industrial Chain
  • 1.3.2 Upstream
  • 1.3.3 Downstream
• 1.4 Industry Situation
  • 1.4.1 Industrial Policy
  • 1.4.2 Product Preference
  • 1.4.3 Economic/Political Environment
• 1.5 SWOT Analysis

2 Market Analysis by Types

• 2.1 Overall Market Performance(Volume)
  • 2.1.1 CT-2009 Market Performance (Volume)
  • 2.1.2 POL-6014 Market Performance (Volume)
  • 2.1.3 ARO-AAT Market Performance (Volume)
  • 2.1.4 ALNAAT-02 Market Performance (Volume)
  • 2.1.5 Others Market Performance (Volume)
• 2.2 Overall Market Performance(Value)
  • 2.2.1 CT-2009 Market Performance (Value)
  • 2.2.2 POL-6014 Market Performance (Value)
  • 2.2.3 ARO-AAT Market Performance (Value)
  • 2.2.4 ALNAAT-02 Market Performance (Value)
  • 2.2.5 Others Market Performance (Value)

3 Market Assessment by Application

• 3.1 Overall Market Performance (Volume)
  • 3.1.1 Clinic Market Performance (Volume)
  • 3.1.2 Hospital Market Performance (Volume)
  • 3.1.3 Others Market Performance (Volume)

4 Manufacturers Profiles/Analysis

• 4.1 Adverum Biotechnologies, Inc.
  • 4.1.1 Adverum Biotechnologies, Inc. Profiles
  • 4.1.2 Adverum Biotechnologies, Inc. Product Information
  • 4.1.3 Adverum Biotechnologies, Inc. Alpha- Antitrypsin Deficiency Treatment Business Performance
  • 4.1.4 Adverum Biotechnologies, Inc. Alpha- Antitrypsin Deficiency Treatment Business Development and Market Status
• 4.2 Alnylam Pharmaceuticals, Inc.
  • 4.2.1 Alnylam Pharmaceuticals, Inc. Profiles
  • 4.2.2 Alnylam Pharmaceuticals, Inc. Product Information
  • 4.2.3 Alnylam Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Business Performance
  • 4.2.4 Alnylam Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Business Development and Market Status
• 4.3 Applied Genetic Technologies Corporation
  • 4.3.1 Applied Genetic Technologies Corporation Profiles
  • 4.3.2 Applied Genetic Technologies Corporation Product Information
  • 4.3.3 Applied Genetic Technologies Corporation Alpha- Antitrypsin Deficiency Treatment Business Performance
  • 4.3.4 Applied Genetic Technologies Corporation Alpha- Antitrypsin Deficiency Treatment Business Development and Market Status
• 4.4 Arrowhead Pharmaceuticals, Inc.
  • 4.4.1 Arrowhead Pharmaceuticals, Inc. Profiles
  • 4.4.2 Arrowhead Pharmaceuticals, Inc. Product Information
  • 4.4.3 Arrowhead Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Business Performance
  • 4.4.4 Arrowhead Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Business Development and Market Status
• 4.5 Carolus Therapeutics, Inc.
  • 4.5.1 Carolus Therapeutics, Inc. Profiles
  • 4.5.2 Carolus Therapeutics, Inc. Product Information
  • 4.5.3 Carolus Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Business Performance
  • 4.5.4 Carolus Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Business Development and Market Status
• 4.6 Cevec Pharmaceuticals GmbH
  • 4.6.1 Cevec Pharmaceuticals GmbH Profiles
  • 4.6.2 Cevec Pharmaceuticals GmbH Product Information
  • 4.6.3 Cevec Pharmaceuticals GmbH Alpha- Antitrypsin Deficiency Treatment Business Performance
  • 4.6.4 Cevec Pharmaceuticals GmbH Alpha- Antitrypsin Deficiency Treatment Business Development and Market Status
• 4.7 Dicerna Pharmaceuticals, Inc.
  • 4.7.1 Dicerna Pharmaceuticals, Inc. Profiles
  • 4.7.2 Dicerna Pharmaceuticals, Inc. Product Information
  • 4.7.3 Dicerna Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Business Performance
  • 4.7.4 Dicerna Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Business Development and Market Status
• 4.8 Digna Biotech, S.L.
  • 4.8.1 Digna Biotech, S.L. Profiles
  • 4.8.2 Digna Biotech, S.L. Product Information
  • 4.8.3 Digna Biotech, S.L. Alpha- Antitrypsin Deficiency Treatment Business Performance
  • 4.8.4 Digna Biotech, S.L. Alpha- Antitrypsin Deficiency Treatment Business Development and Market Status
• 4.9 Editas Medicine, Inc.
  • 4.9.1 Editas Medicine, Inc. Profiles
  • 4.9.2 Editas Medicine, Inc. Product Information
  • 4.9.3 Editas Medicine, Inc. Alpha- Antitrypsin Deficiency Treatment Business Performance
  • 4.9.4 Editas Medicine, Inc. Alpha- Antitrypsin Deficiency Treatment Business Development and Market Status
• 4.10 Grifols, S.A.
  • 4.10.1 Grifols, S.A. Profiles
  • 4.10.2 Grifols, S.A. Product Information
  • 4.10.3 Grifols, S.A. Alpha- Antitrypsin Deficiency Treatment Business Performance
  • 4.10.4 Grifols, S.A. Alpha- Antitrypsin Deficiency Treatment Business Development and Market Status
• 4.11 Inhibrx
• 4.12 Intellia Therapeutics, Inc.
• 4.13 International Stem Cell Corporation
• 4.14 Ionis Pharmaceuticals, Inc.
• 4.15 Kamada Ltd.
• 4.16 Polyphor Ltd.
• 4.17 ProMetic Life Sciences Inc.
• 4.18 rEVO Biologics, Inc.
• 4.19 Sangamo BioSciences, Inc.

5 Market Performance for Manufacturers

• 5.1 USA Alpha- Antitrypsin Deficiency Treatment Sales (K Units) and Market Share by Manufacturers (2014-2020)
• 5.2 USA Alpha- Antitrypsin Deficiency Treatment Revenue (M USD) and Market Share by Manufacturers (2014-2020)
• 5.3 USA Alpha- Antitrypsin Deficiency Treatment Price (USD/Unit) of Manufacturers (2014-2020)
• 5.4 USA Alpha- Antitrypsin Deficiency Treatment Gross Margin of Manufacturers (2014-2020)
• 5.5 Market Concentration

6 Regions Market Performance for Manufacturers

• 6.1 Northeast Market Performance for Manufacturers
  • 6.1.1 Northeast Alpha- Antitrypsin Deficiency Treatment Sales (K Units) and Share of Manufacturers (2014-2020)
  • 6.1.2 Northeast Alpha- Antitrypsin Deficiency Treatment Revenue (M USD) and Share of Manufacturers (2014-2020)
  • 6.1.3 Northeast Alpha- Antitrypsin Deficiency Treatment Price (USD/Unit) of Manufacturers (2014-2020)
  • 6.1.4 Northeast Alpha- Antitrypsin Deficiency Treatment Gross Margin of Manufacturers (2014-2020)
  • 6.1.5 Market Concentration
• 6.2 Midwest Market Performance for Manufacturers
  • 6.2.1 Midwest Alpha- Antitrypsin Deficiency Treatment Sales (K Units) and Share of Manufacturers (2014-2020)
  • 6.2.2 Midwest Alpha- Antitrypsin Deficiency Treatment Revenue (M USD) and Share of Manufacturers (2014-2020)
  • 6.2.3 Midwest Alpha- Antitrypsin Deficiency Treatment Price (USD/Unit) of Manufacturers (2014-2020)
  • 6.2.4 Midwest Alpha- Antitrypsin Deficiency Treatment Gross Margin of Manufacturers (2014-2020)
  • 6.2.5 Market Concentration
• 6.3 South Market Performance for Manufacturers
  • 6.3.1 South Alpha- Antitrypsin Deficiency Treatment Sales (K Units) and Share of Manufacturers (2014-2020)
  • 6.3.2 South Alpha- Antitrypsin Deficiency Treatment Revenue (M USD) and Share of Manufacturers (2014-2020)
  • 6.3.3 South Alpha- Antitrypsin Deficiency Treatment Price (USD/Unit) of Manufacturers (2014-2020)
  • 6.3.4 South Alpha- Antitrypsin Deficiency Treatment Gross Margin of Manufacturers (2014-2020)
  • 6.3.5 Market Concentration
• 6.4 West Market Performance for Manufacturers
  • 6.4.1 West Alpha- Antitrypsin Deficiency Treatment Sales (K Units) and Share of Manufacturers (2014-2020)
  • 6.4.2 West Alpha- Antitrypsin Deficiency Treatment Revenue (M USD) and Share of Manufacturers (2014-2020)
  • 6.4.3 West Alpha- Antitrypsin Deficiency Treatment Price (USD/Unit) of Manufacturers (2014-2020)
  • 6.4.4 West Alpha- Antitrypsin Deficiency Treatment Gross Margin of Manufacturers (2014-2020)
  • 6.4.5 Market Concentration

7 USA Alpha- Antitrypsin Deficiency Treatment Market Performance (Sales Point)

• 7.1 USA Alpha- Antitrypsin Deficiency Treatment Sales (K Units) and Market Share by Regions (2014-2020)
• 7.2 USA Alpha- Antitrypsin Deficiency Treatment Revenue (M USD) and Market Share by Regions (2014-2020)
• 7.3 USA Alpha- Antitrypsin Deficiency Treatment Price (USD/Unit) by Regions (2014-2020)
• 7.4 USA Alpha- Antitrypsin Deficiency Treatment Gross Margin by Regions (2014-2020)

8 Development Trend for Regions (Sales Point)

• 8.1 USA Alpha- Antitrypsin Deficiency Treatment Sales and Growth, Sales Value and Growth Rate(2014-2020)
• 8.2 Northeast Alpha- Antitrypsin Deficiency Treatment Sales and Growth, Sales Value and Growth Rate(2014-2020)
• 8.3 Midwest Alpha- Antitrypsin Deficiency Treatment Sales and Growth, Sales Value and Growth Rate(2014-2020)
• 8.4 South Alpha- Antitrypsin Deficiency Treatment Sales and Growth, Sales Value and Growth Rate(2014-2020)
• 8.5 West Alpha- Antitrypsin Deficiency Treatment Sales and Growth, Sales Value and Growth Rate(2014-2020)

9 Upstream Source, Technology and Cost

• 9.1 Upstream Source
• 9.2 Technology
• 9.3 Cost

10 Channel Analysis

• 10.1 Market Channel
• 10.2 Distributors

11 Consumer Analysis

• 11.1 Clinic Industry
• 11.2 Hospital Industry
• 11.3 Others Industry

12 Market Forecast 2021-2026

• 12.1 Sales (K Units), Revenue (M USD), Market Share and Growth Rate 2021-2026
  • 12.1.1 USA Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD) and Market Share by Regions 2021-2026
  • 12.1.2 USA Alpha- Antitrypsin Deficiency Treatment Sales (K Units) and Growth Rate 2021-2026
  • 12.1.3 Northeast Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
  • 12.1.4 Midwest Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
  • 12.1.5 South Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
  • 12.1.6 West Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
  • 12.1.7 Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
  • 12.1.8 Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
  • 12.1.9 Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
  • 12.1.10 Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
• 12.3 Sales (K Units), Revenue (M USD) by Types 2021-2026
  • 12.3.1 Overall Market Performance
  • 12.3.2 CT-2009 Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
  • 12.3.3 POL-6014 Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
  • 12.3.4 ARO-AAT Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
  • 12.3.5 ALNAAT-02 Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
• 12.4 Sales by Application 2021-2026
  • 12.4.1 Overall Market Performance
  • 12.4.2 Clinic Sales and and Growth Rate 2021-2026
  • 12.4.3 Hospital Sales and and Growth Rate 2021-2026
  • 12.4.4 Others Sales and and Growth Rate 2021-2026
• 12.5 Price (USD/Unit) and Gross Profit
  • 12.5.1 USA Alpha- Antitrypsin Deficiency Treatment Price (USD/Unit) Trend 2021-2026
  • 12.5.2 USA Alpha- Antitrypsin Deficiency Treatment Gross Profit Trend 2021-2026

13 Conclusion